Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function) High retention rate with 90% of patients entering the OLE remaining in the study at one year Canvuparatide was generally well tolerated with no new safety signals during the OLE PK supports once-weekly dosing, with low peak-to-trough ratio and stable exposure Phase 3 pivotal trial remains on track to initiate in Q3 2026 Company to host conference call today at 8:00 a.m. ET CARMEL, Ind. and BURLINGTON, Mass., June 12, 2026 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage...

Village Farms Launches Pure Sunfarms Pink Kush Cured Resin VapeCanada’s all-time number one strain now available as a true-to-flower cured resin vape.Canada’s all-time number one strain now available as a true-to-flower cured resin vape Launch positions Pure Sunfarms’ iconic Pink Kush in Canada’s fastest-growing cannabis category DELTA, British Columbia, June 12, 2026 (GLOBE NEWSWIRE) — Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) today announced the launch of the Pure Sunfarms Pink Kush Cured Resin 510 Vape, bringing Canada’s all-time number one selling strain into the fastest-growing category of the Canadian cannabis market. Pure Sunfarms’ Pink Kush holds the distinction of being the all-time top-selling strain across major Canadian markets for five years running,1 making it one...

TORONTO, June 12, 2026 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM and OTCQB: ILLMF) (“illumin” or the “Company”), the advertising technology platform that enables you to win your next customer, today announced that at its annual general meeting of shareholders held on June 11, 2026 (the “Meeting”), all director nominees proposed by the management of the Corporation were elected as directors of the Corporation, as follows:Nominee Votes “For” % Votes For Votes “Against” % Votes AgainstSheldon Pollack 14,257,496 93.849% 934,510 6.151%David Andrews 14,745,609 97.062% 446,397 2.938%Bruce Barker 14,212,007 93.549% 979,999 6.451%Tal Hayek 14,970,403 98.541% 221,603 1.459%Paul Khawaja 14,410,161 94.854% 781,845 5.146%In addition, the other items of business at the Meeting, being the...

— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations — New post hoc analysis of Phase 1b/2 ALPHA-STAR study of investigational navenibart demonstrates consistent reductions in HAE attack rates across patient subgroups, supporting ongoing Phase 3 evaluation as a potential long-acting therapeutic option for the broad HAE population RESEARCH TRIANGLE PARK, N.C., June 12, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new clinical data and real-world evidence for ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older, in addition to new data from the Phase 1b/2 multicenter, dose-ranging,...

Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies  KT-621 parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the results from the Phase 1 study of KT-621, its first-in-class, oral STAT6 degrader, in healthy Japanese adults were shared in an oral presentation at the Japanese Dermatological Association (JDA) Annual Meeting being held June 11-14, 2026, in...

ALMATY, Kazakhstan, June 12, 2026 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (Nasdaq: KSPI) announces that the following resolutions were duly passed at its Extraordinary General Meeting on 11 June 2026: 1. To approve the agenda of the Extraordinary General Meeting of Shareholders of JSC Kaspi.kz: 1)   Approval of the agenda;2)   Payment of dividends on common shares of JSC Kaspi.kz and approval of the amount of dividend per common share;3)   Determination of the number and the term of powers and election of members of JSC Kaspi.kz’s Counting commission. 2. To approve dividends to be paid within the period set by law: 1)   dividend amount of KZT 850 (eight hundred and fifty tenge) per common share of JSC Kaspi.kz;2)   dividend is paid for period 1Q 2026;3)   commencement date of dividend payments: 11 June 2026;4)   the list...

WUHU, China, June 12, 2026 (GLOBE NEWSWIRE) — In June 2026, Chery Group’s premium new energy brand LEPAS is accelerating its global deliveries in full swing. The brand embeds that pre-match composure into every detail of our Leopard Aesthetics and Elegant Technology – so every ride carries the confidence of a champion walking onto the pitch. The whistle is about to blow, and the world is buzzing with mounting excitement. Players have completed their final preparations—refining focus through rigorous training, embracing ritual-like calm, and steadying their minds as the big moment approaches. The closer the game, the calmer the rhythm. This is precisely what LEPAS embodies in its Year of Global Delivery: as the world heats up, elegance stays cool. Mastering Strength, Steering with EleganceFootball is not only about winning,...

LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare.  “We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pioneering scientific research into new treatment options for patients in need. As a clinician, it is tremendously rewarding to see this vision become...

Following the capital increase of €15 million (including the share premium) through an accelerated book building process (ABB) on 10 June 2026, 311,203 new shares are being issued today (12 June 2026). In accordance with Article 15 of the Law of 2 May 2007 on the disclosure of major shareholdings (‘Transparency Law’), Ascencio SA is publishing the following information:the new share capital amounts to €41,443,128.00; the total number of shares with a voting right at the annual general meeting of shareholders becomes 6,907,188 (the denominator); the newly issued shares entitle the holders to the full amount of profit generated as from 1 October 2025 and to the same dividend as the other shares; the total number of voting rights is 6,907,188; there are no other shares or rights conferring voting rights, nor are there any non-voting  shares....

OSLO, Norway (12 June 2026) – TGS, through its Prediktor division, will deliver its PowerView™ Plant SCADA solution for Scatec’s Grootfontein solar power project in South Africa, supporting reliable operations and centralized monitoring across three large-scale photovoltaic plants.Located near Ceres and Touws River in the Western Cape, the Grootfontein development consists of three solar plants with a combined capacity of 225 MWAC (273 MWp) connected to the national grid operated by Eskom. As part of the project, Prediktor PowerView™ enables real-time monitoring, control and performance management across the entire facility. The platform integrates operational data from plant infrastructure, including inverters, trackers, substations, weather stations and metering systems, to provide a unified operational view. The system...